Contact

News Coverage

News Coverage
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55…
 
Read Morelaunch
News Coverage
Calidi Biotherapeutics Presents Systemic Oncolytic Platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting
Calidi Biotherapeutics Presents Systemic Oncolytic platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting San Diego, CA – June 2, 2025 — Calidi Biotherapeutics Inc. (NYSE American:…
 
Read Morelaunch
News Coverage
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the…
 
Read Morelaunch
News Coverage
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly…
 
Read Morelaunch
News Coverage
Calidi’s Contribution To The Treatment Of COVID-19
In A Short Time, The Novel Coronavirus Disease (COVID-19) Has Destructively Impacted Both The People Of The World And The Global Economy On A Historic Scale. As Of April 27th…
 
Read Morelaunch